Stroke:无症状颈动脉狭窄患者进行CABG合并CEA术的5年结果

2022-09-11 MedSci原创 MedSci原创

在5年的随访中,与单独的CABG相比,尽管在统计上并不显著,联合CABG+CEA与较高的卒中或死亡比率有关。

尽管缺乏随机试验的证据,对于有冠状动脉疾病并伴有无症状的严重颈动脉狭窄的患者进行冠状动脉旁路移植术(CABG)和颈动脉内膜切除术(CEA)的联合治疗已被广泛采用。最近有研究表明,与单纯的CABG相比,CABG+CEA后30天内发生中风或死亡的风险更高。

近期,来自CABGCAS协作组织报告了CABG与无CEA后的长期结果。CABACS是一项随机、对照、多中心、公开的试验。接受CABG的无症状严重(≥70%)颈动脉狭窄患者被分配为CABG+CEA或单独CABG,随访时间为5年。主要次要终点包括非致命性中风或死亡,任何死亡和任何非致命性中风。

结果显示,5年后,各组之间的中风或死亡比率没有明显差异(CABG+CEA 40.6% [95% CI, 0.285-0.536],单独CABG 35.0% [95% CI, 0.231-0.484];P=0.58)。在CABG+CEA之后的任何时候,非致命性中风的发生率都较高(1年:19.3%对7.1%,P=0.09;5年:29.4%对18.8%,P=0.25)。两组5年内的全因死亡率相似(CABG+CEA:25.4%对单独CABG:23.3%,RR=1.148[95%CI,0.560-2.353];P=0.71)。亚组分析没有发现年龄、性别、术前改良的Rankin量表和中心对结果事件的任何明显影响。

在5年的随访中,与单独的CABG相比,尽管在统计上并不显著,联合CABG+CEA与较高的卒中或死亡比率有关。这主要是由于CABG+CEA后围手术期的风险不明显。

 

参考文献:

Five-Year Results of Coronary Artery Bypass Grafting With or Without Carotid Endarterectomy in Patients With Asymptomatic Carotid Artery Stenosis: CABACS RCT.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1843675, encodeId=153218436e516, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Wed Jul 19 21:21:14 CST 2023, time=2023-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967451, encodeId=a102196e451ea, content=<a href='/topic/show?id=ba21590e1f9' target=_blank style='color:#2F92EE;'>#无症状颈动脉狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59071, encryptionId=ba21590e1f9, topicName=无症状颈动脉狭窄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 23 14:21:14 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485298, encodeId=acde1485298c3, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488658, encodeId=2e2f1488658a1, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496960, encodeId=a38a1496960ed, content=<a href='/topic/show?id=217b33259df' target=_blank style='color:#2F92EE;'>#动脉狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33259, encryptionId=217b33259df, topicName=动脉狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4ae9287436, createdName=piaojinhua, createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1843675, encodeId=153218436e516, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Wed Jul 19 21:21:14 CST 2023, time=2023-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967451, encodeId=a102196e451ea, content=<a href='/topic/show?id=ba21590e1f9' target=_blank style='color:#2F92EE;'>#无症状颈动脉狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59071, encryptionId=ba21590e1f9, topicName=无症状颈动脉狭窄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 23 14:21:14 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485298, encodeId=acde1485298c3, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488658, encodeId=2e2f1488658a1, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496960, encodeId=a38a1496960ed, content=<a href='/topic/show?id=217b33259df' target=_blank style='color:#2F92EE;'>#动脉狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33259, encryptionId=217b33259df, topicName=动脉狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4ae9287436, createdName=piaojinhua, createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1843675, encodeId=153218436e516, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Wed Jul 19 21:21:14 CST 2023, time=2023-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967451, encodeId=a102196e451ea, content=<a href='/topic/show?id=ba21590e1f9' target=_blank style='color:#2F92EE;'>#无症状颈动脉狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59071, encryptionId=ba21590e1f9, topicName=无症状颈动脉狭窄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 23 14:21:14 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485298, encodeId=acde1485298c3, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488658, encodeId=2e2f1488658a1, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496960, encodeId=a38a1496960ed, content=<a href='/topic/show?id=217b33259df' target=_blank style='color:#2F92EE;'>#动脉狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33259, encryptionId=217b33259df, topicName=动脉狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4ae9287436, createdName=piaojinhua, createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1843675, encodeId=153218436e516, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Wed Jul 19 21:21:14 CST 2023, time=2023-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967451, encodeId=a102196e451ea, content=<a href='/topic/show?id=ba21590e1f9' target=_blank style='color:#2F92EE;'>#无症状颈动脉狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59071, encryptionId=ba21590e1f9, topicName=无症状颈动脉狭窄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 23 14:21:14 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485298, encodeId=acde1485298c3, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488658, encodeId=2e2f1488658a1, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496960, encodeId=a38a1496960ed, content=<a href='/topic/show?id=217b33259df' target=_blank style='color:#2F92EE;'>#动脉狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33259, encryptionId=217b33259df, topicName=动脉狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4ae9287436, createdName=piaojinhua, createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=)]
    2022-09-12 shizhenshan
  5. [GetPortalCommentsPageByObjectIdResponse(id=1843675, encodeId=153218436e516, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Wed Jul 19 21:21:14 CST 2023, time=2023-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967451, encodeId=a102196e451ea, content=<a href='/topic/show?id=ba21590e1f9' target=_blank style='color:#2F92EE;'>#无症状颈动脉狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59071, encryptionId=ba21590e1f9, topicName=无症状颈动脉狭窄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 23 14:21:14 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485298, encodeId=acde1485298c3, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488658, encodeId=2e2f1488658a1, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496960, encodeId=a38a1496960ed, content=<a href='/topic/show?id=217b33259df' target=_blank style='color:#2F92EE;'>#动脉狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33259, encryptionId=217b33259df, topicName=动脉狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4ae9287436, createdName=piaojinhua, createdTime=Mon Sep 12 02:21:14 CST 2022, time=2022-09-12, status=1, ipAttribution=)]

相关资讯

Eur Heart J:高敏心肌肌钙蛋白I水平有助于CABG术后决策

对于hs-cTnI,CABG术后患者的术后管理应使用比目前推荐的更高临界值。

JACC:肾功能轻度受损对接受多血管冠状动脉血运重建手术的患者预后没有影响

在通过PCI或CABG进行血管重建的多血管疾病患者中,肾功能轻度下降与主要综合结果和死亡率的风险增加没有明显关系。

EHJ:三血管或左主干患者手术怎么选?选PCI还是CABG还真有讲究!

在3VD和/或LMCAD患者中,MAG可能是更理想的CABG配置,以实现比PCI更低的长期全因死亡率。

EHJ:CABG术后心肌损伤对预后有长期影响,如何预测更为准确?

4UD和ARC标准是短期及长期预后强有力的预测因素。

JACC:合并糖尿病的多血管病变患者选择CABG和PCI因人而异

FREEDOM研究后续随访近8年的数据显示,对于合并糖尿病的多血管病变患者,冠状动脉旁路手术(CABG)优于经皮冠状动脉介入治疗(PCI)。

STS 2022:对于多支冠状动脉疾病,带动脉导管的CABG可能是比PCI更好的选择

接受动脉导管 CABG 的患者生存率显著提高,心力衰竭、再入院和主要不良心脑血管事件显著减少。

拓展阅读

Eur Heart J:左主干冠状动脉疾病患者PCI和CABG疗效比较

在这项非随机研究中在对已知和未知混杂因素进行多变量调整后,与PCI相比,LMCA患者接受CABG治疗后与更低的死亡率和更低的MACCE发生率相关。

AHA 2022:在冠状动脉旁路移植术(CABG)中桡动脉与右胸内动脉/隐静脉的15年预后比较(RAPCO-RITA研究)

RAPCO研究,是比较冠状动脉旁路移植术(CABG)中桡动脉与右胸内动脉/隐静脉的对比。10年的随访结果,发表在2020年Circulation上。显示,桡动脉和游离右侧乳内动脉的10年通畅率分别为8

JACC:合并糖尿病的多血管病变患者选择CABG和PCI因人而异

FREEDOM研究后续随访近8年的数据显示,对于合并糖尿病的多血管病变患者,冠状动脉旁路手术(CABG)优于经皮冠状动脉介入治疗(PCI)。

EHJ:三血管或左主干患者手术怎么选?选PCI还是CABG还真有讲究!

在3VD和/或LMCAD患者中,MAG可能是更理想的CABG配置,以实现比PCI更低的长期全因死亡率。

JACC:肾功能轻度受损对接受多血管冠状动脉血运重建手术的患者预后没有影响

在通过PCI或CABG进行血管重建的多血管疾病患者中,肾功能轻度下降与主要综合结果和死亡率的风险增加没有明显关系。

Eur Heart J:高敏心肌肌钙蛋白I水平有助于CABG术后决策

对于hs-cTnI,CABG术后患者的术后管理应使用比目前推荐的更高临界值。